Stifel raised its price target on Array BioPharma (NASDAQ: ARRY) to $23.00 (from $20.00) while maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Array BioPharma (ARRY) PT Raised to $24 at Cantor FitzgeraldFebruary 8, 2018 6:34 AM Array BioPharma (ARRY) PT Raised to $20 at Leerink PartnersFebruary 7, 2018 7:40 AM Array BioPharma (ARRY) PT Raised to $19 at CowenFebruary 7, 2018 7:05 AM Array Biopharma (ARRY) Tops Q2 EPS by 6cFebruary 6, 2018 8:08 AM Form 8-K ARRAY BIOPHARMA INC For: Feb 06February 6, 2018 8:06 AM Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018February 6, 2018 8:05 AM Array Biopharma (ARRY) Says Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median OS in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS TrialFebruary 6, 2018 8:03 AM